Autoimmune Hepatitis Pipeline Insight, 2019

Publisher Name :
Date: 13-Sep-2019
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

Autoimmune Hepatitis (Lupoid hepatitis)

Overview:

"Autoimmune Hepatitis (AIH) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autoimmune Hepatitis pipeline landscape is provided which includes the disease overview and Autoimmune Hepatitis treatment guidelines. The assessment part of the report embraces, in depth Autoimmune Hepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autoimmune Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Autoimmune Hepatitis (AIH) Understanding

"Autoimmune hepatitis (AIH) formerly known as Lupoid hepatitis is a non-contagious, chronic, inflammatory, autoimmune disease in which one's own immune system attacks healthy, normal liver cells. The cause of liver cell destruction in this disease is unclear, but may be related to an imbalance in some of the immune system cells (effector and regulatory). The persistent inflammation within the liver observed in AIH can result in scarring, ultimately leading to cirrhosis, liver failure requiring a liver transplant, and even death. AIH is about 4 times more common in females than males and is commonly associated with other autoimmune conditions including type 1 diabetes, Hashimoto's thyroiditis, and celiac disease. There are two forms of this disease. Type 1, or classic, autoimmune hepatitis is the more common form. This is the form that mostly affects young women and is often associated with other autoimmune diseases. Type 2 autoimmune hepatitis is less common and generally affects girls between the ages of 2 and 14.

Autoimmune Hepatitis (AIH) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Autoimmune Hepatitis (AIH) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Autoimmune Hepatitis (AIH) pipeline report covers 10+ companies. Some of the key players include TaiwanJ Pharmaceuticals (JKB-122), Novartis Pharmaceuticals (VAY736), BioIncept (sPIF) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Autoimmune Hepatitis (AIH) Analytical Perspective by DelveInsight

- In-depth Autoimmune Hepatitis (AIH) Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

- Autoimmune Hepatitis (AIH) Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

- The Autoimmune Hepatitis report provides an overview of therapeutic pipeline activity for Autoimmune Hepatitis across the complete product development cycle including all clinical and non-clinical stages

- It comprises of detailed profiles of Autoimmune Hepatitis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

- Detailed Autoimmune Hepatitis Research and Development progress and trial details, results wherever available, are also included in the pipeline study

- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Autoimmune Hepatitis

Reasons to Buy

- Establish a comprehensive understanding of the current pipeline scenario across Autoimmune Hepatitis to formulate effective R&D strategies

- Assess challenges and opportunities that influence Autoimmune Hepatitis R&D

- Develop strategic initiatives by understanding the focus areas of leading companies.

- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

- Get in detail information of each product with updated information on each project along with key milestones

- Devise Autoimmune Hepatitis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Autoimmune Hepatitis to enhance and expand business potential and scope

- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Autoimmune Hepatitis Pipeline Insight, 2019

Table of Contents

1. Report Introduction
2. Autoimmune Hepatitis (AIH) (Lupoid hepatitis)
2.1. Autoimmune Hepatitis (AIH) Disease Overview
2.2. Autoimmune Hepatitis (AIH) History
2.3. Autoimmune Hepatitis (AIH) Symptoms
2.4. Autoimmune Hepatitis (AIH) Causes
2.5. Autoimmune Hepatitis (AIH) Pathophysiology
2.6. Autoimmune Hepatitis (AIH) Diagnosis
2.6.1. Diagnostic Guidelines
3. Autoimmune Hepatitis (AIH) Current Treatment Patterns
3.1. Treatment Guidelines
4. Autoimmune Hepatitis (AIH)- DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Autoimmune Hepatitis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Autoimmune Hepatitis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Autoimmune Hepatitis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. Autoimmune Hepatitis Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. Autoimmune Hepatitis -Products Analysis
6.1. Product Profiles
6.1.1. JKB-122: TaiwanJ Pharmaceuticals
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. VAY736: Novartis Pharmaceuticals
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. sPIF: BioIncept
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
To be continued in the report…………………………
7. Recent Technologies
8. Autoimmune Hepatitis Key Companies
8.1. Jenken Biosciences
8.2. BioIncept
8.3. MorphoSys
8.4. Novartis
8.5. Incyte Corporation
8.6. Protalix Biotherapeutics
8.7. Revive Therapeutics
8.8. Sanyal Biotechnology
8.9. Mitsubishi Tanabe
8.10. Parvus Therapeutics
8.11. Enzo Biochem
9. Autoimmune Hepatitis Key Products
9.1. JKB 122
9.2. Preimplantation factor
9.3. Ianalumab
9.4. Epacadostat
9.5. PRX 106
9.6. Research programme: liver disorder therapeutics
9.7. Azathioprine oral dispersible
9.8. Research programme: navacims
9.9. SK1 I
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Autoimmune Hepatitis - Unmet Needs
12. Autoimmune Hepatitis - Future Perspectives
13. Appendix
14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation

List of Tables

TABLE 1 Diagnostic Guidelines
TABLE 2 Treatment Guidelines
TABLE 3 Assessment Summary
TABLE 4 Company-Company Collaborations (Licensing / Partnering) Analysis
TABLE 5 Autoimmune Hepatitis (AIH) Acquisition Analysis
TABLE 6 Assessment by Phase of Development
TABLE 7 Assessment by Product Type (Mono / Combination)
TABLE 8 Assessment by Stage and Product Type
TABLE 9 Assessment by Route of Administration
TABLE 10 Assessment by Stage and Route of Administration
TABLE 11 Assessment by Molecule Type
TABLE 12 Assessment by Stage and Molecule Type
TABLE 13 Assessment by MOA
TABLE 14 Assessment by Stage and MOA
TABLE 15 Late Stage Products (Phase-III)
TABLE 16 Mid Stage Products (Phase-II)
TABLE 17 Early Stage Products (Phase-I)
TABLE 18 Pre-clinical and Discovery Stage Products
TABLE 19 Inactive Products
TABLE 20 Dormant Products
TABLE 21 Discontinued Products

List of Figures

Figure 1 Disease Overview
Figure 2 History
Figure 3 Symptoms
Figure 4 Causes
Figure 5 Pathophysiology
Figure 6 Diagnostic Guidelines
Figure 7 Treatment Guidelines
Figure 8 Autoimmune Hepatitis (AIH) companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9 Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10 Autoimmune Hepatitis (AIH) Acquisition Analysis
Figure 11 Assessment by Phase of Development
Figure 12 Assessment by Product Type (Mono / Combination)
Figure 13 Assessment by Stage and Product Type
Figure 14 Assessment by Route of Administration
Figure 15 Assessment by Stage and Route of Administration
Figure 16 Assessment by Molecule Type
Figure 17 Assessment by Stage and Molecule Type
Figure 18 Assessment by MOA
Figure 19 Assessment by Stage and MOA
Figure 20 Late Stage Products (Phase-III)
Figure 21 Mid Stage Products (Phase-II)
Figure 22 Early Stage Products (Phase-I)
Figure 23 Pre-clinical and Discovery Stage Products
Figure 24 Inactive Products
Figure 25 Dormant Products
Figure 26 Discontinued Products
Figure 27 Unmet Needs
  • Hepatitis B Vaccine Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 19-Dec-2019        Price: US 3000 Onwards        Pages: 138
    Hepatitis B Vaccine Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Hepatitis B Vaccine industry with a focus on the Chinese market. The report provides key statistics on the market status of the Hepatitis B Vaccine manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Hepati......
  • 2020 Global Thymosin a1 Market Outlook
    Published: 16-Dec-2019        Price: US 2900 Onwards        Pages: 90
    Thymosins can enhance body immunity and are mainly used in the treatment of hepatitis and tumors. Thymosins mainly include Thymosin, Thymopentin and Thymosin a1. Thymosin a1 is a high-end thymosin. Clinical trials suggest it may be useful in cystic fibrosis, septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, TB, severe acute respiratory syndrome, and lung infections in critically ill patients., and for chronic hepatitis B. It also has been studied fo......
  • Global Hepatitis A Vaccine Market Growth 2019-2024
    Published: 12-Dec-2019        Price: US 3660 Onwards        Pages: 134
    According to this study, over the next five years the Hepatitis A Vaccine market will register a 2.2% CAGR in terms of revenue, the global market size will reach US$ 705.3 million by 2024, from US$ 647.3 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Hepatitis A Vaccine business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis A Vaccine mar......
  • Global Hepatitis A Vaccine Market Research (2015-2019) and Future Forecast (2020-2025)
    Published: 10-Dec-2019        Price: US 3300 Onwards        Pages: 120
    Summary The report forecast global Hepatitis A Vaccine market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025. The report offers detailed coverage of Hepatitis A Vaccine industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Hepatitis A Vaccine by geography. The report splits the market size, by volume and v......
  • Sofosbuvir Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 05-Dec-2019        Price: US 3000 Onwards        Pages: 137
    Sofosbuvir Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Sofosbuvir industry with a focus on the Chinese market. The report provides key statistics on the market status of the Sofosbuvir manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Sofosbuvir market covering all im......
  • Global Human Hepatitis B Immunoglobulin Market Professional Survey Report 2019
    Published: 27-Nov-2019        Price: US 3500 Onwards        Pages: 117
    The global Human Hepatitis B Immunoglobulin market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Human Hepatitis B Immunoglobulin volume and value at global level, regional level and company level. From a global perspective, this report represents overall Human Hepatitis B Immunoglobulin market size by analyzing historical data and future prospect. Regionally, this report catego......
  • 2017-2025 World Hepatitis A Vaccine Market Research Report (by Product Type, End-User / Application and Regions / Countries)
    Published: 15-Nov-2019        Price: US 2800 Onwards        Pages: 98
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. The report includes as follows: The report provides current data, historical overview and future forecast. The report includes an in-depth analysis of the Global market for Hepatitis A Vaccine , covering Global total and ......
  • Global Thymosin Beta 4 Antibody Industry Market Research Report
    Published: 17-Oct-2019        Price: US 2960 Onwards        Pages: 107
    The Thymosin Beta 4 Antibody market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Thymosin Beta 4 Antibody industrial chain, this report mainly elaborates the definition, types, applications and major players of Thymosin Beta 4 Antibody market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise p......
  • Global Hepatitis A Vaccine Market Study 2016-2026, by Segment (Liver Inactivated Vaccine, Live Attenuated Vaccine) , by Market (Hospitals, Other Medical Institutions) , by Company (GlaxoSmithKline, Merck Sharp & Dohme Corp,)
    Published: 12-Oct-2019        Price: US 1800 Onwards        Pages: 56
    Summary The global Hepatitis A Vaccine market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026. Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.): - Liver Inactivated Vaccine - Live Attenuated Vaccine Demand Coverage (Market Size & Forecast, Consumer Distribution): - Hospitals - Other Medical Institutions Company Coverage (Sales data, Main Products &......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs